Secondary hyperparathyroidism is one of the complications of chronic renal failure. (PTH) is a disease of excessive secretion. Excessive secretion of PTH leads to the accumulation of phosphorus and calcium dissolved from bone in the systemic cardiovascular system, resulting in hyperkalemia, hyperphosphatemia and arteriosclerosis, leading to cardiovascular diseases. Villa card peptide drugs in parathyroid calcium receptor to induce the PTH it can inhibit the excessive secretion, reduce blood phosphorus and calcium levels, besides have the effect that reduce blood PTH also can prevent the excessive loss of calcium phosphate bone disease, caused by such as joint pain, bone malnutrition and so on.
Veracatide is the world’s first calcium-mimicking body for a calcium-sensing receptor (CaSR) agonist and a novel therapeutic agent for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. In terms of the number of patients receiving hemodialysis, there were more than 660,000 patients in the United States and 340,000 patients in Japan in 2020. Two American and Japanese pharmaceutical companies have jointly developed a veracatide drug and an oral veracatide-like tablet. In addition, velacatide has been developed as an intravenous injection, which can be reliably administered from the venous side of the dialysis circuit under the control of a physician when returning to the blood at the end of dialysis. In addition, the risk of drug interactions is low because it is almost immune to metabolic enzymes, helping the active D-amino acid peptide skeleton not to be metabolized in the body. It can still be expected to act continuously for a long time until it is removed during the next dialysis. Thus, adherence can be improved and the medication burden of patients reduced.
In China, there were more than 440,000 patients in 2019, but the total number of patients with kidney dysfunction and requiring dialysis treatment in 2019 has exceeded 2.2 million. There is no mature domestic veracatide drug product at present. There is a huge market space here. It is worthwhile for research institutes and pharmaceutical companies with technical capability to develop and mass-produce new vecaratide drugs.
Post time: Jul-30-2024